Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718216 | 0.83 | CA14 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL24318147 | 0.81 | CTSS (0.31) | HDAC6HDAC1HDAC2CTSSCTSK | |
| SCHEMBL18400312 | 0.80 | CA14 (0.36) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL4813607 | 0.78 | HDAC6 (0.32) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL27471031 | 0.78 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL9178624 | 0.78 | HDAC6 (0.32) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL4813601 | 0.78 | HDAC6 (0.32) | HDAC6HDAC1HDAC2USP30CA1 | |
| SCHEMBL3244669 | 0.77 | DPP4 (0.33) | HDAC6HDAC1HDAC2 | |
| SCHEMBL23107149 | 0.77 | CA1 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL23773857 | 0.77 | CA1 (0.36) | HDAC6HDAC1HDAC2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385386-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF | ANGEX PHARMACEUTICAL, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385386-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF | MAP3K20, PNCK, CDC42BPG | HDAC6 581/4885HDAC1 587/4885HDAC2 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.